SCHEMBL4158503

SCHEMBL4158503

COC(=O)Cc1cccc(-c2cncc(-c3cc(-c4cccc(C)n4)nc4[nH]ccc34)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 2/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C8 P10632 1/20 0.43
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
CDK8 P49336 7/20 0.38
CFD P00746 1/20 0.37
NPC1 O15118 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPK1 P28482 1/20 0.36
WNT3A P56704 1/20 0.36
SYK P43405 1/20 0.36
ROCK1 Q13464 1/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
NFKB1 P19838 1/20 0.36
RAB9A P51151 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4158310 0.92 TGFBR1 (0.43) TGFBR1CYP3A4CYP2C8CYP11B1CYP11B2
SCHEMBL3797278 0.91 TGFBR1 (0.44) TGFBR1CYP3A4CYP2C8CYP11B1CYP11B2
SCHEMBL4149109 0.90 TGFBR1 (0.40) TGFBR1CYP3A4CYP2C8CYP11B1CYP11B2
SCHEMBL4156341 0.88 CYP3A4 (0.39) TGFBR1CYP3A4CYP2C8CYP11B1CYP11B2
SCHEMBL4155004 0.87 CDK8 (0.49) TGFBR1CYP3A4CYP2C8CDK8CFD
SCHEMBL27808284 0.87 TGFBR1 (0.42) TGFBR1CYP3A4CYP2C8CDK8CFD
SCHEMBL4158256 0.85 CDK8 (0.49) TGFBR1CYP3A4CYP2C8CDK8CFD
SCHEMBL3796138 0.85 TGFBR1 (0.42) TGFBR1CYP3A4CYP2C8CDK8HPGDS
SCHEMBL4149178 0.84 VSIR (0.43) TGFBR1CYP3A4CYP2C8CDK8CFD
SCHEMBL3804408 0.84 TGFBR1 (0.46) TGFBR1CYP3A4CYP2C8CDK8TGFBR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314112-B2 Pyrrolopyrimidines and pyrrolopyridines NOVARTIS AG (CH) 2012-11-20 US disclosed
US-20090181941-A1 Pyrrolopyrimidines and Pyrrolopyridines NOVARTIS AG (CH) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181941-A1 Pyrrolopyrimidines and Pyrrolopyridines ALK, ACVR1, PTPN4 TGFBR1 128/4885CYP3A4 111/4885CYP2C8 1297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.